Announcement: UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine
14 March 2019
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, highlighting REPROCELL’s recent work — combining the ability to access human fresh tissues with clinical data, pharmacology and ‘omics’.
Press Release: REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development
12 March 2019
Glasgow, UK. — REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.
Press Release: REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories
28 February 2019
Beltsville, MD, USA. — REPROCELL Inc. and Fox Chase, Ltd., a member of the Fox Chase Cancer Center family of organizations, have formed a joint venture to begin operations of multi-site biosample repository facilities globally.
Upcoming Event: European Crohn’s and Colitis Organisation Congress on Inflammatory Bowel Diseases
6–9 March 2019 / Copenhagen, Denmark
Come see us at Booth 11 to find our more. Contact us to schedule a meeting.
Upcoming Event: American Association for Cancer Research 2019 Annual Meeting
20 March – 3 April 2019 / Atlanta, Georgia, USA
Come see us at Booth 2349 near AACRcentral to find our how we can help you advance your research.
Announcement: Appointment of New Distributor in China
1 February 2019
3D epithelial barrier assays in vitro: How to get the best balance between practicability and physiological relevance
13 March 2019
Bio-engineered 3D tissue models using Alvetex Scaffold restore the Z-dimension which is missing in flat-surface cell culture, allowing for the building of mucosal and sub-mucosal compartments in a single model.
Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling
22 February 2019
The conventional drug discovery pathway is a very inefficient process. REPROCELL provides services for generating iPSCs from various tissue sources using our state-of-the-art StemRNA 3rd Gen Reprogramming technology.
The gut microbiome in health and disease: the future for diagnosis and treatment of IBD and IBS?
12 February 2019
A new method for distinguishing between IBD (inflammatory bowel disease) and IBS (irritable bowel syndrome) could be on the horizon.
Tissue Sourcing for the Development of iPSC-derived Disease Models
6 February 2019
Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level.
TISSUE SPOTLIGHT: Skin
5 November 2018
Skin disease is one of the leading causes of global disease burden, affecting millions of people world-wide.
TISSUE SPOTLIGHT: Intestines
25 October 2018
Improving our understanding of intestinal disorders and developing new effective treatments is critical.
Our Popular Products